Represents the profit sharing ration between the company and the counterparty under the agreement.

No definition available.

Name:	ptgx_CollaborativeAgreementProfitSharePercentage
Namespace Prefix:	ptgx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the milestone additional payment eligible to receive from a collaborative arrangement.

+ References

No definition available.

+ Details

Name:	ptgx_CollaborativeArrangementMilestoneAdditionalPaymentEligibleToReceive
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the milestone payment amount eligible to receive from a collaborative arrangement.

+ References

No definition available.

+ Details

Name:	ptgx_CollaborativeArrangementMilestonePaymentEligibleToReceive
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of annual net sales determining the royalty percentage under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	ptgx_CollaborativeArrangementThresholdAnnualNetSales
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of maximum sales milestone revenue.

+ References

No definition available.

+ Details

Name:	ptgx_MaximumSalesMilestoneRevenue
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the percentage of royalties on net sales.

+ References

No definition available.

+ Details

Name:	ptgx_PercentageOfRoyaltiesOnNetSalesPercent
Namespace Prefix:	ptgx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents upcoming potential development and regulatory milestone payments receivable.

+ References

No definition available.

+ Details

Name:	ptgx_UpcomingPotentialDevelopmentAndRegulatoryMilestonesPayments
Namespace Prefix:	ptgx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=ptgx_TakedaPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ptgx_LicenseAndCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ptgx_FoodAndDrugAdministrationApprovalOfNewDrugApplicationForRusfertideInPvMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=ptgx_ExerciseOfFullOptOutRightDuringInitialOptOutPeriodMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=ptgx_ExerciseOfFullOptOutRightMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=ptgx_AnnualNetSalesUpto1.5BillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_WeightedAverageMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=ptgx_AnnualNetSalesAbove1.5BillionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Subsequent Events (Details) - Takeda Pharmaceuticals - USD ($) $ in Millions		1 Months Ended
	Apr. 28, 2026	Apr. 28, 2026	Apr. 30, 2024	Jan. 31, 2024	Mar. 31, 2026
License And Service
Subsequent Events
Profit (loss) share on U.S. profits and losses			50.00%
License and collaboration agreement \| Minimum
Subsequent Events
Percentage of royalties			10.00%	14.00%
License and collaboration agreement \| Maximum
Subsequent Events
Collaborative arrangement, milestone payment, eligible to receive			$ 305.0
Additional payment eligible to receive from a collaborative arrangement				$ 200.0
Percentage of royalties			17.00%	29.00%
License and collaboration agreement \| Food And Drug Administration approval Of new drug application for rusfertide in PV
Subsequent Events
Upcoming potential development and regulatory milestone payments receivable				$ 50.0
License and collaboration agreement \| Exercise of full opt out right during the initial opt out period \| Maximum
Subsequent Events
Collaborative arrangement, milestone payment, eligible to receive				200.0
License and collaboration agreement \| Exercise of full opt-out right
Subsequent Events
Upcoming potential development and regulatory milestone payments receivable					$ 775.0
License and collaboration agreement \| Exercise of full opt-out right \| Maximum
Subsequent Events
Collaborative arrangement, milestone payment, eligible to receive				975.0
License and collaboration agreement \| Exercise of full opt-out right \| Food And Drug Administration approval Of new drug application for rusfertide in PV
Subsequent Events
Upcoming potential development and regulatory milestone payments receivable				$ 75.0
Subsequent Events \| License And Service \| Exercise of full opt-out right
Subsequent Events
Profit (loss) share on U.S. profits and losses		50.00%
Subsequent Events \| License and collaboration agreement \| Maximum
Subsequent Events
Additional payment eligible to receive from a collaborative arrangement	$ 200.0	$ 200.0
Subsequent Events \| License and collaboration agreement \| Exercise of full opt out right during the initial opt out period \| Maximum
Subsequent Events
Collaborative arrangement, milestone payment, eligible to receive	200.0	200.0
Subsequent Events \| License and collaboration agreement \| Exercise of full opt-out right \| Food And Drug Administration approval Of new drug application for rusfertide in PV
Subsequent Events
Upcoming potential development and regulatory milestone payments receivable	$ 75.0	75.0
Subsequent Events \| License and collaboration agreement \| Annual net Sales Up to 1.5 billion
Subsequent Events
Milestone revenue		$ 775.0
Subsequent Events \| License and collaboration agreement \| Annual net Sales Up to 1.5 billion \| Minimum
Subsequent Events
Percentage of royalties	14.00%
Subsequent Events \| License and collaboration agreement \| Annual net Sales Up to 1.5 billion \| Maximum
Subsequent Events
Percentage of royalties	29.00%
Annual net sales	$ 1,500.0
Subsequent Events \| License and collaboration agreement \| Annual net Sales Up to 1.5 billion \| Weighted average
Subsequent Events
Percentage of royalties	21.00%
Subsequent Events \| License and collaboration agreement \| Annual net sales above 1.5 billion
Subsequent Events
Percentage of royalties	29.00%
Subsequent Events \| License and collaboration agreement \| Annual net sales above 1.5 billion \| Minimum
Subsequent Events
Annual net sales	$ 1,500.0